Community pharmacies across Northern Ireland are scrambling to secure alternative flu vaccine supplies after Viatris confirmed it will no longer fulfil pre ordered influenza vaccine orders for the 2026/27 season.
The unexpected decision has left affected contractors urgently contacting vaccine manufacturers, wholesalers and buying groups in an attempt to replace stock they believed had already been secured.
What has happened?
Pharmacies that placed advance orders for the 2026/27 flu vaccination season have been informed that Viatris will no longer supply the vaccine stock ordered.
The issue relates to a change in the recommended influenza strain composition for the coming season. This change was communicated by the World Health Organization in February.
However, manufacturing delays have meant Viatris is now unable to fulfil any orders within the required timeframe.
The timing of the announcement has created significant concern across the sector, with many pharmacies having placed orders months ago and planned their seasonal vaccination activity on the basis that this stock had been secured.
Pharmacies had already planned for the season ahead
Community pharmacies typically place flu vaccine orders many months before the vaccination season begins.
This allows contractors to plan staffing, patient communications, appointment capacity, workplace clinics and wider vaccination activity.
Many pharmacies across Northern Ireland will already have completed much of this preparation for the 2026/27 season on the basis that their vaccine stock had been secured.
The withdrawal of these orders now leaves affected pharmacies attempting to source replacement stock at a point when manufacturers have largely finalised production and allocations.
Unlike other pharmacy products, flu vaccines cannot easily be manufactured or redistributed at short notice. Production is planned well in advance, based on anticipated demand and the recommended vaccine composition for the coming season.
This means additional stock may be extremely limited once suppliers have closed their order books.
Private vaccination services face the greatest pressure
The immediate concern is expected to centre on private flu vaccination services.
Many community pharmacies purchase dedicated stock to provide vaccinations for people who are not eligible through publicly funded programmes, as well as for local employers and organisations.
Private flu vaccination activity can include:
- Individual private patient appointments
- Workplace vaccination clinics
- Employer-funded vaccination programmes
- Vaccinations for people who fall outside national eligibility criteria
Pharmacies may also have existing agreements with local businesses to vaccinate employees ahead of the winter period.
Where clinics or corporate programmes have already been arranged, contractors may now face the difficult task of securing replacement stock or revising their planned service.
The situation could also lead to increased competition between providers for any vaccine allocations that remain available within the UK market.
Limited alternatives may remain
Contractors affected by the cancellation are being encouraged to contact alternative vaccine providers as soon as possible.
Some manufacturers and wholesalers may hold small quantities of unallocated stock, cancelled orders or contingency supplies, although availability is likely to vary considerably.
Pharmacies should also speak with their buying groups, wholesale partners and service providers to establish whether any collective arrangements or reserved allocations are available.
Group purchasing organisations may be in a stronger position to identify remaining supply or coordinate replacement orders across multiple pharmacies.
However, contractors should be prepared for the possibility that the vaccine type, pack size, delivery schedule or commercial terms may differ from their original Viatris order.
Potential financial and operational impact
The cancellation may create both financial and operational consequences for affected pharmacies.
Contractors may already have invested time and money in marketing private vaccination services, arranging clinics, recruiting vaccinators or agreeing services with employers.
Replacement stock may also be available at a different price from the original order, placing pressure on margins for private vaccination services.
Pharmacies may need to review:
- The number of private vaccination appointments they can offer
- Workplace or employer clinic commitments
- Marketing activity already scheduled
- Staffing and vaccination capacity
- Patient communications
- Pricing for private vaccinations
- Cancellation terms within any corporate agreements
Where pharmacies have already accepted bookings, they should avoid cancelling appointments until all replacement supply options have been explored.
It may also be sensible to temporarily limit future bookings until stock availability has been confirmed.
What pharmacies should do now
Affected contractors should take immediate steps to understand the scale of the issue within their own business.
This should include confirming which orders have been cancelled, the quantity of vaccine affected and the services that depended on that stock.
Pharmacies should then:
- Contact alternative vaccine manufacturers and wholesalers
- Speak with buying groups and procurement partners
- Confirm whether any existing orders with other suppliers remain secure
- Review private and workplace clinic commitments
- Avoid accepting additional bookings that cannot currently be supported
- Keep clear records of cancelled orders and related correspondence
- Review any financial losses or additional costs caused by the cancellation
Pharmacies operating across several branches may also wish to review whether confirmed stock can be allocated differently across their estate.
Any reallocation would need to take account of local patient demand, existing bookings, delivery arrangements and appropriate vaccine storage requirements.
No indication of a wider change to the vaccination programme
There is currently no indication that the cancellation represents a change to the recommended 2026/27 flu vaccination programme itself.
The issue relates to the fulfilment of vaccine orders placed with Viatris rather than a wider change in national vaccination recommendations.
However, the loss of a planned source of supply could place additional pressure on the wider market, particularly if a significant number of pharmacies and other vaccination providers are affected.
The full impact will depend on the total volume of cancelled stock and the ability of other manufacturers and suppliers to provide replacement vaccines.